stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.11
0.92
−3.53%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Gross margin
Caris Life Sciences,�Inc.'s gross margin over the twelve months to 30 September 2026 was 0.00%, down 66.4 percentage points from fiscal 2025 (66.4%). That is below the Biotechnology industry median of 65.2% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 66.4% | 23.03 |
| FY2024 | 43.4% | 14.20 |
| FY2023 | 29.2% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (68.10) |
| Jun 2026 | 68.1% | 2.71 |
| Mar 2026 | 65.4% | (10.04) |
| Dec 2025 | 75.4% | 7.40 |
| 5 more quarters | Free account |
Gross margin against peers
| Company | Gross margin |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 100.0% |
| SYRE Spyre Therapeutics, Inc. compare | 100.0% |
| IBRX ImmunityBio, Inc. compare | 99.3% |
| KRYS Krystal Biotech, Inc. compare | 94.3% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 91.0% |
| TGTX TG Therapeutics, Inc. compare | 82.4% |
| TWST Twist Bioscience Corporation compare | 52.0% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| CAI Caris Life Sciences,�Inc. | 0.00% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement